Search results for " metabolic"

showing 10 items of 1022 documents

Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases

2018

Since the discovery of HLA 60 years ago, it has contributed to the understanding of the immune system as well as of the pathogenesis of several diseases. Aside from its essential role in determining donor-recipient immune compatibility in organ transplantation, HLA genotyping is meanwhile performed routinely as part of the diagnostic work-up of certain autoimmune diseases. Considering the ability of HLA to influence thymic selection as well as peripheral anergy of T cells, its role in the pathogenesis of autoimmunity is understandable. The aim of this paper is to provide a brief overview of the role and current clinical relevance of HLA-B27 in spondyloarthritis and HLA-B51 in Behçet's disea…

musculoskeletal diseases0301 basic medicinemedicine.medical_specialtyReviewBehcet's diseaseDiseaseHuman leukocyte antigenmedicine.disease_causeOrgan transplantationAutoimmune DiseasesAutoimmunityPathogenesisEpitopes03 medical and health sciencesImmune system0302 clinical medicineRheumatologyHLA AntigensInternal medicineHumansImmunology and AllergyMedicineClinical significanceskin and connective tissue diseases030203 arthritis & rheumatologyHLA-B27business.industryHistocompatibility Antigens Class IInutritional and metabolic diseasesmedicine.diseaseRheumatologyeye diseasesstomatognathic diseases030104 developmental biologyRheumatoid arthritisImmunologybusiness
researchProduct

Interaction of allopurinol with phenprocoumon in man.

1977

Conditions in two patients on long-term phenprocoumon (Marcumar®) treatment are reported who had signs of phenprocoumon overdosage when given simultaneously allopurinol. The determination of phenprocoumon plasma concentrations in one patient showed that phenprocoumon accumulates for several weeks during treatment with allopurinol. Signs of phenprocoumon overdosage thus can appear long time after starting allopurinol treatment.

musculoskeletal diseasesAdultMalecongenital hereditary and neonatal diseases and abnormalitiesAllopurinolMyocardial InfarctionAllopurinolPharmacologyPhenprocoumonDrug DiscoveryMedicineHumansDrug InteractionsBlood CoagulationGenetics (clinical)integumentary systembusiness.industrynutritional and metabolic diseasesGeneral Medicine4-HydroxycoumarinsDrug interactionMiddle AgedPlasma concentrationPhenprocoumonMolecular MedicineBlood Coagulation TestsbusinessMathematicsmedicine.drugKlinische Wochenschrift
researchProduct

Osteoprotegerin: a new biomarker for impaired bone metabolism in complex regional pain syndrome?

2014

Abstract Osteoprotegerin (OPG) is important for bone remodeling and may contribute to complex regional pain syndrome (CRPS) pathophysiology. We aimed to assess the value of OPG as a biomarker for CRPS and a possible correlation with radiotracer uptake in 3-phase bone scintigraphy (TPBS). OPG levels were analyzed in 23 CRPS patients (17 women; mean age 50 ± 9.0 years; disease duration: 12 weeks [IQR 8–24]), 10 controls (6 women; mean age 58 ± 9.6 years) and 21 patients after uncomplicated fractures (12 women; mean age: 43 ± 15 years; time after fracture: 15 weeks [IQR: 6–22]). The CRPS and control patients also underwent TPBS. OPG in CRPS patients was significantly increased by comparison wi…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyGastroenterologySensitivity and SpecificityBone remodeling03 medical and health sciences0302 clinical medicineOsteoprotegerinInternal medicinemedicineHumans030304 developmental biology0303 health sciencesmedicine.diagnostic_testReceiver operating characteristicbusiness.industryArea under the curveOsteoprotegerinMiddle Agedmedicine.diseasePathophysiologyBone Diseases MetabolicAnesthesiology and Pain MedicineEndocrinologyComplex regional pain syndromeNeurologyBone scintigraphyBiomarker (medicine)FemaleNeurology (clinical)business030217 neurology & neurosurgeryBiomarkersComplex Regional Pain SyndromesPainReferences
researchProduct

HLA class II haplotypes differentiate between the adult autoimmune polyglandular syndrome types II and III.

2013

Background: Genetics of the adult autoimmune polyglandular syndrome (APS) is poorly understood. Aim: The aim of this study was to gain further insight into the genetics of the adult APS types. Site: The study was conducted at a university referral center. Methods: The human leukocyte antigen (HLA) class II alleles, haplotypes, and genotypes were determined in a large cohort of patients with APS, autoimmune thyroid disease (AITD), and type 1 diabetes and in healthy controls by the consistent application of high-resolution typing at a four-digit level. Results: Comparison of the allele and haplotype frequencies significantly discriminated patients with APS vs AITD and controls. The HLA class…

musculoskeletal diseasesHla class iiAdultMaleendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismClinical BiochemistryGenes MHC Class IIHuman leukocyte antigenBiochemistryDiagnosis DifferentialYoung AdultEndocrinologyGene FrequencyAutoimmune Polyglandular SyndromeGenotypeMedicineHumansGenetic Predisposition to DiseaseTypingAlleleskin and connective tissue diseasesChildPolyendocrinopathies AutoimmuneType 1 diabetesbusiness.industryBiochemistry (medical)Haplotypenutritional and metabolic diseasesMiddle Agedmedicine.diseaseHaplotypesCase-Control StudiesImmunologyFemalebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous oxidative DNA b…

2002

The Cockayne syndrome B (CSB) gene product is involved in the repair of various types of base modifications in actively transcribed DNA sequences. To investigate its significance for the repair of endogenous oxidative DNA damage, homozygous csb(-/-)/ogg1(-/-) double knockout mice were generated. These combine the deficiency of CSB with that of OGG1, a gene coding for the mammalian repair glycosylase that initiates the base excision repair of 7,8-dihydro-8-oxoguanine (8-oxoG). Compared to ogg1(-/-) mice, csb(-/-)/ogg1(-/-) mice were found to accumulate with age severalfold higher levels of oxidited purine modifications in hepatocytes, splenocytes and kidney cells. In contrast, the basal (ste…

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesCancer ResearchDNA RepairTranscription GeneticDNA damageDNA repairBiologyGene productMicechemistry.chemical_compoundGeneticsAnimalsPoly-ADP-Ribose Binding ProteinsMolecular BiologyGeneDNA PrimersMice KnockoutBase SequenceHomozygoteDNA HelicasesDeoxyguanosinenutritional and metabolic diseasesBase excision repairMolecular biologyOxidative StressDNA Repair EnzymesBiochemistrychemistry8-Hydroxy-2'-DeoxyguanosineDNA glycosylaseDNADNA DamageNucleotide excision repairOncogene
researchProduct

Granuloma anulare disseminatum als seltene Nebenwirkung von Allopurinol

1995

During long-term therapy of hyperuricaemia with allopurinol (300 mg/d) two patients developed generalized granuloma annulare. The diagnoses were confirmed by histology; concomitant diseases, especially diabetes mellitus, were not detectable. Following discontinuation of allopurinol therapy, cutaneous granulomas healed without relapse. Hyperuricaemia could be controlled by low-purine diet and medication avoiding allopurinol. The clinical history of our two patients suggested a causal connection between allopurinol therapy and generalized granuloma annulare. For this reason we rate the development of this disease in both cases as a rare but significant side effect of allopurinol. This should …

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyChemotherapySide effectbusiness.industrymedicine.medical_treatmentnutritional and metabolic diseasesAllopurinolDermatologymedicine.diseaseConcomitant drugDermatologyDiscontinuationGranulomaConcomitantmedicinebusinessmedicine.drugGeneralized granuloma annulareDer Hautarzt
researchProduct

Mucopolysaccharidoses and other lysosomal storage diseases.

2013

Mucopolysaccharidosis and other lysosomal storage diseases are rare, chronic, and progressive inherited diseases caused by a deficit of lysosomal enzymes. Patients are affected by a wide variety of symptoms. For some lysosomal storage diseases, effective treatments to arrest disease progression, or slow the pathologic process, and increase patient life expectancy are available or being developed. Timely diagnosis is crucial. Rheumatologists, orthopedics, and neurologists are commonly consulted due to unspecific musculoskeletal signs and symptoms. Pain, stiffness, contractures of joints in absence of clinical signs of inflammation, bone pain or abnormalities, osteopenia, osteonecrosis, secon…

musculoskeletal diseasesmedicine.medical_specialtyPathologyMucopolysaccharidosisPainOsteochondrodysplasiasHip dysplasia (canine)RheumatologyInternal medicineLysosomal storage diseasemedicineHumansMusculoskeletal DiseasesBone painHip Dislocation CongenitalMuscle contractureHip Contracturebusiness.industryOsteonecrosisMucopolysaccharidosesPrognosismedicine.diseaseOsteopeniaBone Diseases MetabolicEarly DiagnosisHip ContractureOrthopedic surgeryHip JointJointsJoint Diseasesmedicine.symptomLysosomesbusiness
researchProduct

Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis

2009

Abstract Background Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS) type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric rheumatologists demonstrated that Bone and joint manifestations are prominent among most patients with MPS disorders. These life-threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I (l…

musculoskeletal diseasesmedicine.medical_specialtyPediatricscongenital hereditary and neonatal diseases and abnormalitieslcsh:Diseases of the musculoskeletal systemIdursulfaseMucopolysaccharidosisDiseaseRheumatologyInternal medicinemedicineImmunology and AllergyPediatrics Perinatology and Child HealthYoung adultCarpal tunnel syndromeskin and connective tissue diseasesbusiness.industrylcsh:RJ1-570nutritional and metabolic diseaseslcsh:PediatricsEnzyme replacement therapyHypothesismedicine.diseaseRheumatologyJoint painPediatrics Perinatology and Child Healthmedicine.symptomlcsh:RC925-935businessmedicine.drugPediatric Rheumatology
researchProduct

Management of Statin Intolerance in 2018: Still More Questions Than Answers.

2018

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…

myalgiamedicine.medical_specialtyStatinDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classDiseaseReview Article030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePharmacotherapyMedical adviceDiabetes mellitusCardiovascular DiseasemedicineHumansPharmacology (medical)030212 general & internal medicinecardiovascular diseasesAdverse effectIntensive care medicineDietary SupplementHypolipidemic AgentsHypolipidemic Agentbusiness.industrynutritional and metabolic diseasesDisease ManagementGeneral MedicineCholesterol LDLmedicine.diseaseRegimenCardiovascular DiseasesDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitormedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDrug-Related Side Effects and Adverse ReactionHumanAmerican journal of cardiovascular drugs : drugs, devices, and other interventions
researchProduct

Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease

2021

Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32)

nonalcoholic fatty liver disease0301 basic medicinemedicine.medical_specialtyBetatrophinEndocrinology Diabetes and Metabolismmedicine.medical_treatmentbetatrophin030209 endocrinology & metabolismMicrobiologydigestive systemBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceinsulin resistanceInternal medicineNonalcoholic fatty liver diseaseMedicineMolecular BiologyBetatrophin Glucose intolerance Insulin resistance Nonalcoholic fatty liver diseaseTriglyceridebusiness.industryInsulinnutritional and metabolic diseasesLipid metabolismmedicine.diseaseQR1-502digestive system diseases030104 developmental biologyEndocrinologyglucose intolerancechemistrySteatosisbusinessHormoneMetabolites
researchProduct